Janssen Pharmaceutica Nv

Janssen Pharmaceutica

Raymond W Colburn

Scott L Dax

Christopher M Flores

Mark Andrew Youngman

Jay M Matthews

Donald William Ludovici

Christopher A Teleha

Ning Qin

Mingde Xia

Xiaoqing Xu

Mark J Macielag

James J McNally

Kenneth M Wells

Michele C Jetter

Ronald K Russell

Shawn T Branum

Yi Liu

Scott C Youells

Laura M Reaney

Laura Reany

Patricia Andrade-Gordon

Lisa Minor

Bruce P Damiano

Robert Schulingkamp

Jianshen Qi

Dennis Stone

Christopher Van Besien

Laura W Andraka

Laura M Andraka

Xiaoging Xu

Jay M Mathews

James J Mcnally

Laura M Reany

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R, R, R, and Rare defined herein.

Sulfonamides as TRPM8 modulators

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein A, L, R, R, R, and Rare defined herein.

Cold menthol receptor antagonists

The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

Cold menthol receptor-1 antagonists

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein A, L, R, R, Rand Rare defined herein.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, L, Q, R, R, and Rare defined herein.

Administration of U-II to rats caused an increase in the redness or the skin temperature of the ear of the rats. The increase was inhibited by compounds that decease the biological activity of the U-II/UT receptor. Thus, the present invention provides methods of measuring the biological activity of an U-II receptor by monitoring the redness or the skin temperature of the ear of an animal, and the use of the methods to test compounds for their abilities to increase or decrease the biological activity of an U-II receptor.

Method of measuring the biological activity of an urotensin II receptor

Growing community of inventors

Chalfont, PA, United States of America

Raymond W Colburn